Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3278-3288

  Bohndiek, Sarah E ^a   Kettunen, Mikko I ^a   Hu, De En ^a   Witney, Timothy H ^b   Kennedy, Brett W C ^b   Gallagher, Ferdia A ^c   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; FUMARIC ACID; GADOLINIUM PENTETATE; LACTIC ACID; MALIC ACID; PYRUVIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL DEATH; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEMALE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARBON ISOTOPES; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FUMARATES; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRUVIC ACID; STILBENES; TIME FACTORS;

EID: 78650472851     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0706     Document Type: Article

References (42)

1. Hinnen P, Eskens FALM. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65.
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
3. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li L, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998;58:4510-4.
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
5. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
6. Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol ASCO Meeting Abstr 2006;24:5580.
7. Zweifel M, Jayson G, Reed N, Osborne R, Hassan B, Shreeves G, et al. Combretastatin A-4 phosphate (CA4P) carboplatin an paclitaxel in patients with platinum-resistant ovarian cancer. J Clin Oncol ASCO Meeting Abstr 2009;27:5502.
8. Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, et al. Vascular disrupting agents: A novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009;14:612-20.
9. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
10. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular dug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-15.
11. O'Connor JPB, Jackson A, Asselin M, Buckley DL, Parker GJM, Jackson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: Current and future perspectives. Lancet Oncol 2008;9:766-76.
12. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
13. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin A-4 phosphate after repeated administration. Neoplasia 2005;7:779-87.
14. Thoeny HC, Keyzer FD, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: Dynamiccontrast enhanced versus diffusion-weighted MR imaging. Radiology 2005;237:492-9.
15. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104-9. (Pubitemid 47495868)
16. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, et al. Reproducibility and changes in the apparent diffusion coeffi- cients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009;19:2728-38.
17. Zhao S, Moore JV, Waller ML, McGown AT, Hadfield JA, Pettit GR, et al. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med 1999;26:231-8.
18. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67:9337-45.
19. Jadvar H, Parker JA. Infection and Inflammation. London, UK: Springer; 2005. p. 235-42.
20. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158-63.
21. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13: 1382-7.
22. Witney TH, Kettunen MI, Day SE, Hu DE, Lerche M, Wolber J, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009;11:574-82.
23. Gallagher FA, Kettunen MI, Hu D, Jensen PR, Zandt R, Karlsson M, et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]- fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA 2009;106(47):19801-6.
24. Vigneron D, Kurhanewicz J, Nelson S, Larson P, Hu S, von Morze C, et al. Towards clinical studies of hyperpolarized carbon-13 metabolic imaging. In: Proceedings of the 17th annual scientific meeting of the ISMRM; 2009; Hawai'i.
25. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008;453:940-4.
26. Vassault A. Lactate dehydrogenase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. Weinheim: Verlag Chemie GmbH; 1983. p. 118-26.
27. Czok R, Lamprecht W. Pyruvate, phosphoenolpyruvate and D-glycerate- 2-phosphate. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. Verlag Chemie GmbH; 1974. p. 1446-51.
28. Gutmann I, Wahlefeld AW. L-(+)-lactate: Determination with lactate dehydrogenase and NAD. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. Verlag Chemie GmbH; 1974. p. 1464-8.
29. Goldberg ND, Passonneau JV. L-malate and fumarate. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis: Verlag Chemie GmbH; 1974. p. 1600-3.
30. Minowa T, Kawano K, Kuribayashi H, Shiraishi K, Sugino T, Hattori Y, et al. Increase in tumour permeability following TGF-b type I receptorinhibitor treatment observed by dynamic contrast-enhanced MRI. Br J Cancer 2009;101:1884-90.
31. Muruganandham M, Lupu M, Dyke J, Matei C, Linn M, Packman K, et al. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrastenhanced MRI at 1.5T. Mol Cancer Ther 2006;5:1950-7.
32. de Crespigny AJ, Marks MP, Enzmann DR, Moseley ME. Navigated diffusion imaging of normal and ischemic human brain. Magn Reson Med 1995;33:720-8.
33. Allkemper T. Haemorrhage. In: Reimer P, Parizel PM, Stichnoth FA, editors. Clinical MR Imaging: A Practical Approach. 2nd ed.Berlin, Germany:Springer; 2006. p. 64-76.
34. Chen G, Horsman MR, Pedersen M, Pang Q, Stodkilde-Jorgensen H. The effect of combretastatin A4 disodium phosphate and 5,6- dimethyxanthenone-4-acetic acid on water diffusion and blood perfusion in tumors. Acta Oncol 2008;47:1071-6.
35. Horsman MR, Ehrnrooth E, Ladekari M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 2000;42:895-8.
36. Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872-80.
37. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol 2001;2:82-7.
38. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
39. Kettunen MI, Hu D, Witney TH, McLaughlin R, Gallagher FA, Bohndiek SE, et al. Magnetization transfer measurement of exchange between hyperpolarized [1-13C]pyruvate and [1-13C]lactate in a murine lymphoma. Magn Reson Med 2010;63:872-80.
40. Simon MC. Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab 2006;3:150-1.
41. Witney TH, Kettunen MI, Hu D, Gallagher FA, Brindle KM. Detecting response to treatment in human breast adenocarcinoma using a co-administration of hyperpolarized [1-13C]pyruvate and [1,4-13C2]fumarate. In: 18th Scientific Meeting, International Society for Magnetic Resonance in Medicine; 2010; Stockholm.
42. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000;43: 828-36.